UBS Maintains Buy on Elevance Health, Lowers Price Target to $575
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Kevin Caliendo maintains a Buy rating on Elevance Health (NYSE:ELV) but lowers the price target from $610 to $575.
July 13, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS analyst has maintained a Buy rating on Elevance Health but lowered the price target from $610 to $575.
The news is directly about Elevance Health and its price target being lowered by UBS. While the Buy rating is maintained, the lower price target could indicate a slower growth expectation, which might have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100